{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T05:11:45Z","timestamp":1721970705827},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1007\/s00108-007-1999-2","type":"journal-article","created":{"date-parts":[[2008,3,10]],"date-time":"2008-03-10T14:29:29Z","timestamp":1205159369000},"page":"495-501","source":"Crossref","is-referenced-by-count":6,"title":["Neue orale Antidiabetika"],"prefix":"10.1007","volume":"49","author":[{"given":"S.","family":"Fischer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.R.","family":"Bornstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,3,12]]},"reference":[{"key":"1999_CR1","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s11892-003-0079-9","volume":"3","author":"Ahren","year":"2003","unstructured":"Ahren B (2003) Gut peptides and type 2 diabetes mellitus treatment. Curr Diab Rep 3: 365\u2013372","journal-title":"Curr Diab Rep"},{"key":"1999_CR2","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1517\/13543784.15.4.431","volume":"15","author":"Ahren","year":"2006","unstructured":"Ahren B (2006) Vildagliptin: an inhibitor of dipeptidyl peotidase-4 with antidiabetic properties. Expert Opin Investig Drugs 15: 431\u2013442","journal-title":"Expert Opin Investig Drugs"},{"key":"1999_CR3","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.2337\/dc06-0703","volume":"29","author":"Aschner","year":"2006","unstructured":"Aschner P, Kipnes M, Lunceford J et al.; Sitagliptin Study 021 Group (2006) Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 Diabetes. Diabetes Care 29: 2632\u20132637","journal-title":"Diabetes Care"},{"key":"1999_CR4","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.2337\/db06-0812","volume":"55","author":"Bl\u00fcher","year":"2006","unstructured":"Bl\u00fcher M, Engeli S, Kloting M (2006) Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 55: 3053\u20133060","journal-title":"Diabetes"},{"key":"1999_CR5","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2337\/diacare.28.5.1092","volume":"28","author":"DeFronzo","year":"2005","unstructured":"DeFronzo RA, Ratner RE, Han J et al. (2005) Effects of exenatide (Exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with typ 2 diabetes. Diabetes Care 28: 1092\u20131100","journal-title":"Diabetes Care"},{"key":"1999_CR6","unstructured":"Duttaroy A, Voelker F, Merriam K et al. (2005) The DPP-4 inhibitor vildagliptin increases pancreatic beta cell neogenesis and decreases agoptosis. Diabetes (Suppl 1) 54: A14"},{"key":"1999_CR7","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.1210\/en.2003-0323","volume":"144","author":"Fari","year":"2003","unstructured":"Fari L, Bulotta A, Hirshberg B et al. (2003) Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 144: 5149\u20135158","journal-title":"Endocrinology"},{"key":"1999_CR8","first-page":"43","volume":"Herz","author":"Gallwitz","year":"2007","unstructured":"Gallwitz B (2007) DPP-4-Inhibitoren als neue Substanzklasse oraler Antidiabetika. Diabetes Stoffw Herz: 43\u201350","journal-title":"Diabetes Stoffw"},{"key":"1999_CR9","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1056\/NEJMoa073394","volume":"357","author":"Home","year":"2007","unstructured":"Home SJP, Beck-Nielsen H, Gomis R et al. RECORD Study Group (2007) Rosiglitazone evaluated for cardiovascular outcomes \u2013 an interim analysis. N Engl J Med 357: 28\u201338","journal-title":"N Engl J Med"},{"key":"1999_CR10","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2337\/diacare.28.5.1083","volume":"28","author":"Kendall","year":"2005","unstructured":"Kendall DM, Riddle MC, Rosenstock J (2005) Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28: 1083\u20131091","journal-title":"Diabetes Care"},{"key":"1999_CR11","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/(SICI)1096-9136(199804)15:4<290::AID-DIA570>3.0.CO;2-M","volume":"15","author":"Levy","year":"1998","unstructured":"Levy J, Atkinson AB, Bell PM et al. (1998) Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in Type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. Diabet Med 15: 290\u2013296","journal-title":"Diabet Med"},{"key":"1999_CR12","doi-asserted-by":"crossref","unstructured":"Matthaei S, H\u00e4ring HU (2007) Behandlung des Diabetes mellitus Typ 2. Praxisleitlinie der Deutschen Diabetes Gesellschaft. Diabetologie 2 (Suppl 2): S173\u2013S177 http:\/\/www.deutsche-diabetes-gesellschaft.de","DOI":"10.1055\/s-2007-960637"},{"key":"1999_CR13","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.2337\/db05-1602","volume":"55","author":"Mu","year":"2006","unstructured":"Mu J, Woods J, Zhou YP et al. (2006) Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes 55: 1695\u20131704","journal-title":"Diabetes"},{"key":"1999_CR14","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/BF02427280","volume":"29","author":"Nauck","year":"1986","unstructured":"Nauck M, St\u00f6ckmann F, Ebert R, Creutzfeldt W (1986) Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes. Diabetologia 29: 46\u201352","journal-title":"Diabetologia"},{"key":"1999_CR15","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1210\/jcem.87.3.8355","volume":"87","author":"Nauck","year":"2002","unstructured":"Nauck MA, Heimesaat MM, Behle K et al. (2002) Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 87: 239\u20131246","journal-title":"J Clin Endocrinol Metab"},{"key":"1999_CR16","first-page":"1","volume":"Metab","author":"Nauck","year":"2007","unstructured":"Nauck MA, Meininger G, Sheng D et al.; Sitagliptin Study 024 Group (2007) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomised, double-blind, non-inferiority trial. Diabetes Obes Metab: 1\u201312","journal-title":"Diabetes Obes"},{"key":"1999_CR17","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","volume":"356","author":"Nissen","year":"2007","unstructured":"Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: 2457\u20132471","journal-title":"N Engl J Med"},{"key":"1999_CR18","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1001\/jama.294.20.joc50147","volume":"294","author":"Nissen","year":"2005","unstructured":"Nissen SE, Wolski K, Topol EJ (2005) Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 294: 2581\u20132586","journal-title":"JAMA"},{"key":"1999_CR19","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s001250050664","volume":"40","author":"Rachman","year":"1997","unstructured":"Rachman J, Barrow BA, Levy JC, Turner RC (1997) Near-normalisation of diurnal glucose concentrations by continuous administration of glucagons-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia 40: 205\u2013211","journal-title":"Diabetologia"},{"key":"1999_CR20","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.clinthera.2006.10.007","volume":"28","author":"Rosenstock","year":"2006","unstructured":"Rosenstock J, Brazg R, Andryuk P et al.; Sitagliptin Study 019 Group (2006) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor Sitagliptin added to ongoing Pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomised, double-blind, placebo-controlled, parallel-group study. Clin Ther 28: 1556\u20131568","journal-title":"Clin Ther"},{"key":"1999_CR21","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/S0140-6736(06)69571-8","volume":"368","author":"Scheen","year":"2006","unstructured":"Scheen AJ, Finer N, Hollander P et al.; RIO-Diabetes Study Group (2006) Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 368: 1660\u20131672","journal-title":"Lancet"},{"key":"1999_CR22","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1007\/s00063-006-1100-2","volume":"101","author":"Schwarz","year":"2006","unstructured":"Schwarz PE, Schuppenies A, Gruhl U et al. (2006) Pr\u00e4vention des Typ-2-Diabetes in Deutschland. Med Klin 101: 730\u2013736","journal-title":"Med Klin"},{"key":"1999_CR23","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1210\/jcem.86.8.7750","volume":"86","author":"Toft-Nielsen","year":"2001","unstructured":"Toft-Nielsen MB, Damholt MB, Madsbad S et al. (2001) Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 86: 3717\u20133723","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-007-1999-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-007-1999-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-007-1999-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T04:12:07Z","timestamp":1558584727000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-007-1999-2"}},"subtitle":["Klinische Perspektiven"],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["1999"],"URL":"https:\/\/doi.org\/10.1007\/s00108-007-1999-2","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3]]}}}